Rheumatoid arthritis: A case for personalized health care?

Arthritis Care and Research

Volumn 66, Issue 9, 2014, Pages 1273-1280

  Karsdal, Morten A ^a   Bay Jensen, Anne Christine ^a   Henriksen, Kim ^a   Christiansen, Claus ^a   Genant, Harry K ^b   Chamberlain, Chris ^c   Platt, Adam ^d  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b SYNARC INC   (United States)

^c UCB Celltech   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA DRB1 ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; TOFACITINIB;

BONE DENSITY; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE COURSE; DRUG INDUSTRY; GENETIC ASSOCIATION; GENETIC RISK; HEALTH CARE; HUMAN; OSTEOLYSIS; PATIENT SELECTION; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 84906679497     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22289     Document Type: Review

References (56)

1. Smolen JS, Aletaha D,. Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis 2013; 72: 3-6.
2. Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N, et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009; 14: 181-202.
3. Abrahamsen B, Eiken P, Eastell R,. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010; 95: 5258-65.
4. Cooper C, Emkey RD, McDonald RH, Hawker G, Bianchi G, Wilson K, et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88: 4609-15.
5. Cummings SR, San MJ, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-65.
6. Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999; 84: 2363-8.
7. Pao W, Hutchinson KE,. Chipping away at the lung cancer genome. Nat Med 2012; 18: 349-51.
8. Syversen SW, Goll GL, van der Heijde D, Landewe R, Lie BA, Odegard S, et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 2010; 69: 345-51.
9. Upchurch KS, Kay J,. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) 2012; 51 Suppl 6: vi28-36.
10. Kay J, Upchurch KS,. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 2012; 51 Suppl 6: vi5-9.
11. Reynolds A, Koenig AS, Bananis E, Singh A,. When is switching warranted among biologic therapies in rheumatoid arthritis? Expert Rev Pharmacoecon Outcomes Res 2012; 12: 319-33.
12. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
13. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
14. Verweij CL,. Pharmacogenetics: anti-TNF therapy in RA. Towards personalized medicine? Nat Rev Rheumatol 2011; 7: 136-8.
15. Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP,. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010; 39: 425-41.
16. Devine EB, Alfonso-Cristancho R, Sullivan SD,. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy 2011; 31: 39-51.
17. Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013; 72: 329-36.
18. Wang J, Platt A, Upmanyu R, Germer S, Lei G, Rabe C, et al. IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open 2013; 3: e003199.
19. Wang J, Bansal AT, Martin M, Germer S, Benayed R, Essioux L, et al. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J 2013; 13: 235-41.
20. Littman BH,. Tocilizumab and missed personalized medicine opportunities for patients with rheumatoid arthritis? [letter]. Arthritis Rheum 2009; 60: 1565-6.
21. Smith SL, Plant D, Eyre S, Barton A,. The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1118-24.
22. Hogan VE, Holweg CT, Choy DF, Kummerfeld SK, Hackney JA, Teng YK, et al. Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab. Ann Rheum Dis 2012; 71: 1888-94.
23. Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012; 14: R95.
24. Vosslamber S, Raterman HG, van der Pouw Kraan TC, Schreurs MW, von Blomberg BM, Nurmohamed MT, et al. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis 2011; 70: 1153-9.
25. Atzeni F, Talotta R, Salaffi F, Cassinotti A, Varisco V, Battellino M, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013; 12: 703-8.
26. Simsek I,. Predictors of response to TNF inhibitors in rheumatoid arthritis: do we have new tools for personalized medicine? Bull NYU Hosp Jt Dis 2012; 70: 187-90.
27. Van der Helm-van Mil AH, Knevel R, Cavet G, Huizinga TW, Haney DJ,. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology (Oxford) 2013; 52: 839-46.
28. Li W, Sasso EH, Emerling D, Cavet G, Ford K,. Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. Curr Med Res Opin 2013; 29: 85-92.
29. Eastman PS, Manning WC, Qureshi F, Haney D, Cavet G, Alexander C, et al. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal 2012; 70: 415-24.
30. Keystone EC, Combe B, Smolen J, Strand V, Goel N, van Vollenhoven R, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology (Oxford) 2012; 51: 1628-38.
31. Curtis JR, Luijtens K, Kavanaugh A,. Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year. Arthritis Care Res (Hoboken) 2012; 64: 658-67.
32. Curtis JR, Yang S, Chen L, Park GS, Bitman B, Wang B, et al. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis 2012; 71: 206-12.
33. Karsdal MA, Delvin E, Christiansen C,. Protein fingerprints: relying on and understanding the information of serological protein measurements. Clin Biochem 2011; 44: 1278-9.
34. Karsdal MA, Henriksen K, Leeming DJ, Woodworth T, Vassiliadis E, Bay-Jensen AC,. Novel combinations of post-translational modification (PTM) neo-epitopes provide tissue-specific biochemical markers: are they the cause or the consequence of the disease? Clin Biochem 2010; 43: 793-804.
35. Conrozier T, Poole AR, Ferrand F, Mathieu P, Vincent F, Piperno M, et al. Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis. Clin Exp Rheumatol 2008; 26: 430-5.
36. Karsdal MA, Nielsen MJ, Sand JM, Henriksen K, Genovese F, Bay-Jensen AC, et al. Extracellular matrix remodeling: the common denominator in connective tissue diseases possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol 2013; 11: 70-92.
37. Schuppan D, Ruehl M, Somasundaram R, Hahn EG,. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001; 21: 351-72.
38. Bay-Jensen AC, Liu Q, Byrjalsen I, Li Y, Wang J, Pedersen C, et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM-increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem 2011; 44: 423-9.
39. Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem 2010; 43: 899-904.
40. Veidal SS, Vassiliadis E, Bay-Jensen AC, Tougas G, Vainer B, Karsdal MA,. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair 2010; 3: 5.
41. Wislowska M, Jakubicz D, Stepien K, Cicha M,. Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis. Rheumatol Int 2009; 29: 1403-9.
42. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, et al. Serum CrossLaps One Step ELISA: first application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998; 44: 2281-9.
43. Garnero P, Ferreras M, Karsdal MA, NicAmhlaoibh R, Risteli J, Borel O, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003; 18: 859-67.
44. Leeming D, He Y, Veidal S, Nguyen Q, Larsen D, Koizumi M, et al. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 2011; 16: 616-28.
45. Bay-Jensen A, Byrjalsen I, Kenwright A, Platt A, Karsdal MA,. Identification of serological biomarker profiles associated with early response to tocilizumab in rheumatoid arthritis. Ann Rheum Dis 2012; 71 Suppl 3: 96.
46. Siebuhr AS, Bay-Jensen AC, Leeming DJ, Platt A, Byrjalsen I, Christiansen C, et al. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res Ther 2013; 15: R86.
47. Loke YK, Singh S, Furberg CD,. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32-9.
48. Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 134-42.
49. Gruntmanis U, Fordan S, Ghayee HK, Abdullah SM, See R, Ayers CR, et al. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcif Tissue Int 2010; 86: 343-9.
50. Harslof T, Wamberg L, Moller L, Stodkilde-Jorgensen H, Ringgaard S, Pedersen SB, et al. Rosiglitazone decreases bone mass and bone marrow fat. J Clin Endocrinol Metab 2011; 96: 1541-8.
51. What happened to personalized medicine? [editorial]. Nat Biotechnol 2012; 30: 1.
52. Siebuhr AS, Petersen KK, Arendt-Nielsen L, Egsgaard LL, Eskehave T, Christiansen C, et al. Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover. Osteoarthritis Cartilage 2014; 22: 44-50.
53. Karsdal MA, Christiansen C, Ladel C, Henriksen K, Kraus VB, Bay-Jensen AC,. Osteoarthritis: a case for personalized health care? Osteoarthritis Cartilage 2014; 22: 7-16.
54. Dam EB, Loog M, Christiansen C, Byrjalsen I, Folkesson J, Nielsen M, et al. Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers. Arthritis Res Ther 2009; 11: R115.
55. Food and Drug Administration. Paving the way for personalized medicine: FDA's role in a new era of medical product development. Silver Spring (MD): US Department of Health and Human Services, US Food and Drug Administration; 2013.
56. European Commission. Use of '-omics' technologies in the development of personalised medicine. Commission staff working document. 2013.